Twenty of 26 FDA advisory panel members voted Thursday to relax or remove restrictions on GlaxoSmithKline's diabetes drug Avandia. Several panel members expressed support for additional research into the cardiovascular risks associated with the drug, but some experts said it was unlikely funding would be available.

Full Story:
CNN, Reuters

Related Summaries